GALDERMA
30.3.2023 07:01:26 CEST | Business Wire | Press release
Galderma will be presenting the latest data from the Sculptra® (injectable poly-L-lactic acid, PLLA-SCA) Cheek Wrinkle and Alluzience® (abobotulinumtoxinA solution) STAR studies at the 21st Aesthetic & Anti-Aging Medical World (AMWC) Congress, taking place in Monaco, from March 30 to April 1, 2023. Results demonstrate high aesthetic improvement as well as patient and investigator satisfaction for both products, reinforcing the strength of the company’s highly differentiated aesthetic portfolio, and underscoring its commitment to delivering science, innovation, and a premium experience throughout the treatment journey.1,2
Data from the innovative Sculptra Cheek Wrinkle study, a large clinical registration trial in the United States, show the long-lasting effectiveness of the treatment for cheek wrinkle correction over a two-year period.1 Sculptra is the first and original collagen stimulator with the unique PLLA-SCA3,4,5,6,7,8 that addresses the root causes of the skin aging process by stimulating the body’s own collagen production.9 This helps restore the skin’s foundation and structural function, gradually improving the its firmness, increasing skin elasticity and improving skin quality and radiance. Results are natural, progressive and proven to last over two years.10,11,12,13,14
In the study, the response rate at month 12 was significantly higher for Sculptra compared to the control group (71.6% vs 26.1%). At months seven to 12, those treated with Sculptra also had improved dynamic wrinkles, and even greater proportions had improved aesthetic appearance (≥93%), improved radiance, skin tightness, and jawline contour (≥86%). Patient satisfaction was high with ≥92% satisfied with their appearance and agreeing their skin’s natural glow was improved two years after treatment.1
In the 12-month extension study for the Sculptra treated arm, with no additional treatment, response rate remained high with aesthetic improvement rates of ≥94% at months 19-24, supporting maintained effects on wrinkles through two years. Results also demonstrated the safety profile of Sculptra. Sculptra was well tolerated with adverse events mostly mild and transient, and no new treatment-related adverse events reported in the 12-24 month follow-up.1
Galderma will also present the latest data from Alluzience’s first phase IV study, STAR, at AMWC. Approved in Europe in June 2021, Alluzience is Europe’s first ready-to-use (RTU) liquid neuromodulator for the treatment of moderate to severe glabellar lines (GLs - frown lines).
The clinical development program of Alluzience has shown rapid onset of effect, starting on day one, a long duration up to six months and improved psychological well-being after treatment.15 The objective of the STAR study was to assess subject and investigator experience using a RTU versus powder neurotoxin and aesthetic improvement, satisfaction and safety after just one treatment during a six-month follow-up period.2
At month one, almost all (99%) of those treated with Alluzience had aesthetic improvement in GLs at maximum frown, which persisted in ~76% up to month six. At month six, most subjects felt that they looked natural (95%) and refreshed (85%) and were satisfied with their appearance (88%). Results also showed high investigator satisfaction, 100% agreeing that it fulfilled their expectations, was easy to use and learn and required the fewest possible steps for its purpose. In 81% of treatment sessions, investigators preferred using the RTU formulation over powder. In addition, in 97% of treatment sessions, investigators felt that using a RTU solution such as Alluzience resulted in substantially less waste and that this was better for the environment.2
“The results from both of these important and unique studies reinforce
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
|
New techniques and approaches for the heavy face and the latest data from across the portfolio to be showcased at the congress
As a leader in bringing cutting-edge products to market and in providing the scientific community with individualized treatment approaches, training and business support, Galderma’s extensive presence at AMWC demonstrates its ongoing dedication to advancing dermatology for every skin story.
The focus of the Galderma symposium, titled Aesthetic Lives: Lifting the heavy face will explore the aesthetic journey as a long-term endeavor, using Galderma Holistic Individualized Treatments™ (HIT) to discover the aesthetic lives of patients and the medical professionals who treat them as we shape the future of aesthetics. The event will take place on Thursday, March 30 at 2:00 PM in the Prince Pierre Auditorium.
About Sculptra®
SCULPTRA is the first and original injectable collagen stimulator containing microparticles of unique poly-L-lactic acid (PLLA-SCA) which gradually revitalizes the skin’s structural foundation, providing long-term results for more than two years.3-13 SCULPTRA was first approved in 1999 in Europe, and it is currently available in more than 40 countries globally.
SCULPTRA works to stimulate the skin’s own collagen production9 to provide firm and radiant skin. It is suitable for increasing the volume of depressed areas, particularly to correct skin depressions such as skin creases, wrinkles, folds, and scars, and for signs of skin aging.16
About Alluzience®
Alluzience (abobotulinumtoxinA solution) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.17 It should only be administered by a physician with appropriate qualifications and expertise in this treatment using the required equipment.17 Dosing and treatment intervals depend on assessment of the individual patient’s response.17 The treatment interval should be no more frequent than every three months.17 For more information, please see the Summary of Product Characteristics.17
Alluzience is a product under license from Ipsen. Alluzience is a registered trademark of Ipsen. Galderma has an exclusive license from Ipsen to develop, promote and distribute Alluzience in the approved indication in several European countries.
About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. Galderma’s portfolio of flagship brands includes Restylane®, Dysport®, Azzalure®, Alluzience and Sculptra in Injectable Aesthetics; Soolantra®, Epiduo®, Differin®, Aklief®, Epsolay®, Twyneo®, Oracea®, Metvix®, Benzac® and Loceryl® in Therapeutic Dermatology; and Cetaphil® and Alastin® in Dermo-cosmetics. For more information, visit www.galderma.com.
References:
1 Fabi S. Poster presented at AMWC 2023.
2 Chadha P. Poster presented at AMWC 2023.
3 FDA. Summary of safety and effectiveness data. 2023
4 Data on file. MA- 54151
5 Asius J et al. Inventors. US patent US 7,731,758 B2,2021
6 Data on file. MA-53568
7 Mest DR, et al. Dermatol Surg. 2006
8 Bohnert K et al. Plast Reconstr Surg. 2019
9 Hexsel D, Dermatol Surg. Letters and Communications. 2020
10 Baron J. Abstract presented at IMCAS 2023. (MA-54104)
11 Goldberg D et al. Dermatol Surg. 2013
12 Narins RS, et al. J Am Acad Dermatol. 2010
13 Brandt FS, et al. Aesthet Surg J. 2011
14 Data on file. MA-48331
15 Hilton et al. Dermatol Surg 2022;48:1198-202
16 Sculptra IFU. 2018.
17 Alluzience Summary of Product Characteristics, 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005096/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Forrester’s 2027 Budget Planning Guides: After A Year Of Caution, Business And Tech Leaders Are Ready To Invest Again15.7.2026 11:00:00 CEST | Press release
While leaders are betting on growth, in the age of AI, spending more is no longer enough According to Forrester’s (Nasdaq: FORR) 2027 Budget Planning Guides, business and technology leaders are approaching 2027 with renewed confidence as they increasingly accept volatility as a permanent feature of the business environment. After a year of more cautious spending, more than 80% of leaders expect their budgets to increase over the next 12 months, with as many as one-quarter anticipating growth of 10% or more. But planning in the age of AI demands more than bigger budgets: Increasing investment without modernizing operating models, strengthening data foundations, and improving AI readiness will only accelerate fragmented data, duplicated work, and technical debt. To realize AI’s full potential, leaders must rethink their strategies and prioritize investments in operational foundations, governance, and experimentation that drive tangible outcomes. This year, optimism is widespread across f
Post-Quantum’s Algorithm - Classic McEliece - Achieves Global ISO Standardization to Protect the World From Quantum Cyber Attack15.7.2026 10:00:00 CEST | Press release
Ultra-secure encryption algorithm added to ISO standard for Asymmetric Ciphers Classic McEliece is first PQC algorithm to achieve global standardization Organisations in 177 ISO member states can now adopt Classic McEliece to remain secure from attack by both classical and quantum computers Governments including Germany and the Netherlands already recommend the highly secure Classic McEliece algorithm due to its unmatched security credentials It’s proven that today’s encryption is vulnerable to attack by a sufficiently mature quantum computer running Shor’s algorithm - a catastrophic event commonly known as Q-Day. Even before such a cryptographically relevant quantum computer emerges it is known that adversaries are stealing encrypted data now, which can be decrypted later - also known as Harvest Now, Decrypt Later (HNDL). Google’s recent use of Artificial Intelligence (AI) to optimise Shor’s algorithm reduces the number of physical qubits required to break today’s encryption, therefor
Thredd Joins The Visa Agentic Ready Programme, Bringing Agent Network Readiness To Issuers Across Europe, Starting With Zilch15.7.2026 09:00:00 CEST | Press release
Thredd, the AI-first issuer processing platform, today announced it has joined the Visa Agentic Ready programme, enabling issuers across Europe to participate in agent-initiated payments without rebuilding their payments infrastructure. Consumer payments platform Zilch will be among the first issuers on the platform to enable agent-initiated payments for its cardholders. As a processor and enabler, Thredd sits at the trust layer of the payments ecosystem. By joining the programme, Thredd is ready to support Visa and its clients as the market moves into agentic commerce. Agentic commerce introduces a new type of payment initiator: An AI agent acting on a cardholder's behalf. The core payments principles do not change. Cardholder permission, issuer approval, authentication and fraud monitoring all still apply. What changes is how trust is established and enforced at the point an agent transacts. Taking a Zilch customer as an example, a cardholder might ask an AI agent to find a product w
Surgerii Robotics Announces First European Installation of the SHURUI® Single-Port Surgical System at Vall d'Hebron University Hospital15.7.2026 09:00:00 CEST | Press release
Surgerii Robotics today announced the first European installation of its SHURUI Single-Port (SP) Surgical System at Vall d'Hebron University Hospital in Barcelona, Spain, one of Europe's leading academic medical centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713209503/en/ The first pediatric procedure performed with the SHURUI SP system was a nephroureterectomy on a twelve-year-old boy whose kidney and ureter had become infected and non-functional due to multiple stones. The SHURUI SP system is CE-marked for adult and pediatric use, making it the only CE-marked single-port robotic surgical system currently indicated for pediatric procedures in Europe. The installation marks an important milestone in the international expansion of Surgerii Robotics and the introduction of the technology into a major European reference center. As part of this collaboration, Vall d'Hebron University Hospital has become the first hos
SES, Airbus and Dutch Municipality of Noordwijk to Build Satellite Optical Ground Station for EAGLE-115.7.2026 08:50:00 CEST | Press release
The parties signed a ground lease agreement allowing installation of the optical ground station (OGS) at the NL Space Campus SES, a space solutions company, jointly with Airbus Netherlands B.V. signed a ground lease agreement with the Dutch municipality of Noordwijk for a plot at the NL Space Campus, next to the European Space Agency’s (ESA) technical center ESTeC. The facility will host a dedicated optical ground station (OGS) to communicate with the EAGLE-1 satellite and receive quantum safe keys via laser technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714786947/en/ Breaking the ground of the EAGLE-1 Optical Ground Station, Municipality of Noordwijk, the Netherlands. Pictured left to right: Pim van Strien, Alderman for the Municipality of Noordwijk; Rob Postma, President and Managing Director, Airbus Netherlands; Alan Kuresevic, Managing Director, SES Techcom, SES. The station, to be built by Airbus for SES,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom